"It is very rewarding to be at the forefront of cancer immunotherapy and to apply innovative and cutting-edge technologies to gain a glimpse into each patient’s unique immune response against our immunotherapy drugs."
I completed my PhD training with Dr. Stephen Smale at UCLA in the department of microbiology, immunology, and molecular genetics, where I established physiological primary cell assays to elucidate the molecular mechanism of IL-12 gene expression in macrophages and dendritic cells. I then completed a postdoctoral training in immunobiology at Yale University with Dr. Richard Flavell studying the role of TGF-beta and common gamma chain cytokines in CD8 T cell development and function in the context of autoimmunity, anti-pathogen immunity, and cancer immunity. In 2010, I joined the faculty at the Gladstone Institute of Virology and Immunology and UCSF department of microbiology and immunology. My independent academic research focused on using model pathogens and emerging human pathogens, together with mouse genetic models and human primary tissue samples to study how protective innate and adaptive immune responses are elicited and maintained upon mucosal transmission of viral pathogens. We focused on how innate immune responses contribute to priming, differentiation, trafficking, and formation of protective memory T cell.
My passion for human immunology and my vision to apply innovative technologies to study the immune response of patients undergoing cancer immunotherapy brought me to Oncology Biomarker Development (OBD) at Genentech in 2018. At Genentech, I have served as the Biomarker Sub-team Lead (BMSTL) for several of our early stage CIT programs.
Cytometry B Clin Cytom. 2021 Jan;100(1):10-18.
J Virol. 2020 Dec 22;95(2):e01331-20.
Nat Commun. 2019 Sep 25;10(1):4344.
Proc Natl Acad Sci U S A. 2018 Sep 18;115(38):E8939-E8947.
My group focuses on: